OxySure Therapeutics (OTCPK:OXYS) Partners With MedOne Capital for Customer Medical Equipment Leasing
FRISCO, TX--(Marketwired - January 26, 2016)
Julian Ross, Chairman and CEO of OxySure stated: "We have already closed several deals under leasing programs with MedOne and our customers love the easy, fast and flexible approach. In addition, our customers can now enjoy several other benefits when they purchase their lifesaving medical equipment from us, including conservation of capital and tax advantages."
Information about the leasing program can be found here:
A flyer describing the leasing program can be found here:
About OxySure Therapeutics, Inc.
OxySure Therapeutics, Inc. is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products. www.OxySure.com
We believe OxySure Therapeutics is a Long Play with imminent Short Term Gain potential.
They are a "Cutting Edge" Therapeutic/Oxygen/Emergency Medical Device Company that offers exponential growth.
Oxysure in our opinion will one day be the Leader in many areas of Therapeutics Solutions.
Model 615 (life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder")
** (All products are FDA approved)
Current Target Markets
Schools - Universities - Churches - Community/Rec/Senior Centers - Industry - Sports Organizations - Military - Sporting/Rec Centers
Malls - Libraries - Stadiums - Arenas - Airlines - Sufferers of Asthma/COPD
Anywhere you can hang a Fire Extinguisher Model 615/AEDS/QuikClot & Oxy Trac are applicable.
Forward Look to 2016
The company has realized 800% growth since 2012 through year end 2014. They should finish the year (2015) strong and produce between $4 - $5 Million. That would be another leap in revenue of 70-100%.
With the current model for "Organic Growth" in place OxySure should continue to build upon their growth and success. Keep in mind OXYS already has 11 New (TSM's) Territorial Sales Mangers in place for the new year (2016). Each having a minimum Sales Quota of $500,000. If they all meet that standard that will mean another $5,500,000 $5.5 Million in new business/sales of products and revenue. OXYS will eventually have 25-30 (TSM's) in all. 2016 should be a Huge year for them. The biggest year to date producing $10,000,000 - $10 Million or more in revenue.
Robert E. Kreh
Small Cap Solutions, LLC
Disclaimer: You are receiving this message because you have recently requested it and/or in the past expressed an interest in or about information and updates concerning the company OxySure, Systems, Inc., and/or other Micro/Small Cap Companies. This profile has been compiled by Small Cap Solutions, LLC based on information believed to be true. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com or otcmarkets.com Small Cap Solutions, LLC has received cash or Rule 144 Shares from Oxysure Therapeutics, Inc. for investor relations services rendered. Additional inquiries available by email to firstname.lastname@example.org or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclaimer: All Micro/Small Cap Company(ies) profile(s) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered. Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(s)/Broker Dealer(s) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to email@example.com or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.